Fludarabine phosphate is a specialty chemical serving as an active pharmaceutical ingredient (API) and research reagent (≥99% purity by HPLC). It is primarily used in the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies such as non-Hodgkin lymphoma (NHL). As a purine nucleoside antimetabolite analog, it interferes with DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase, leading to cancer cell death. It is employed when other therapies fail, in combination chemotherapy, and in conditioning regimens prior to hematopoietic stem cell transplantation to suppress the immune system. This white to light yellow powder is typically reconstituted for intravenous administration in clinical settings but is supplied here for laboratory research, pharmaceutical development, and synthesis. Careful handling is required due to potential side effects like myelosuppression, immunosuppression, and increased infection risk.